"The voice for cancer physicians and their patients in Massachusetts."

FDA Approves Moxetumomab pasudotox-tdfk (Lumoxiti) for relapsed or refractory HCL

21 Sep 2018 8:13 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved moxetumomab pasudoltox-tdfk (Lumoxiti; AstraZeneca Pharmaceuticals), a CD22-directed cytotoxin indicated for adult patients with relapased or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA). Read full press release. 

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software